In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
复制标题
DOI：
10.1128/aac.46.6.1723-1727.2002
复制
发表时间：
2002-06-01
影响因子：
4.9
通讯作者：
Diekema, DJ
中科院分区：
文献类型：
--
作者：
Pfaller, MA;Messer, SA;Diekema, DJ
比较了雷武康唑和伏立康唑与雷帕霉素13、氟胞嘧啶（5 FC）、伊曲康唑和氟康唑对6,970株念珠菌的体外活性。来自全球200多个医疗中心。雷康唑和伏立康唑对所有念珠菌都非常有效。(MIC 90%的测试分离株被抑制[MIC 90]，0.25 μ g/ml; 98%的MIC为
The in vitro activities of ravuconazole and voriconazole were compared with those of amphotericin 13, flucytosine (5FC), itraconazole, and fluconazole against 6,970 isolates of Candida spp. obtained from over 200 medical centers worldwide. Both ravuconazole and voriconazole were very active against all Candida spp. (MIC at which 90% of the isolates tested are inhibited [MIC90], 0.25 mug/ml; 98% of MICs were